These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 29698196)

  • 21. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.
    Stone PW; Teutsch S; Chapman RH; Bell C; Goldie SJ; Neumann PJ
    Am J Prev Med; 2000 Jul; 19(1):15-23. PubMed ID: 10865159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of classic utilities to published pediatric cost-utility studies.
    Finnell SM; Carroll AE; Downs SM
    Acad Pediatr; 2012; 12(3):219-28. PubMed ID: 22075466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More work is needed on cost-utility analyses of robotic-assisted surgery.
    Bai F; Li M; Han J; Qin Y; Yao L; Yan W; Liu Y; He G; Zhou Y; Ma X; Aboudou T; Guan L; Lu M; Wei Z; Li X; Yang K
    J Evid Based Med; 2022 Jun; 15(2):77-96. PubMed ID: 35715999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.
    Greenberg D; Earle C; Fang CH; Eldar-Lissai A; Neumann PJ
    J Natl Cancer Inst; 2010 Jan; 102(2):82-8. PubMed ID: 20056956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.
    Nerich V; Saing S; Gamper EM; Holzner B; Pivot X; Viney R; Kemmler G
    Breast Cancer Res Treat; 2017 Aug; 164(3):527-536. PubMed ID: 28497177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring costs in cost-utility analyses. Variations in the literature.
    Stone PW; Chapman RH; Sandberg EA; Liljas B; Neumann PJ
    Int J Technol Assess Health Care; 2000; 16(1):111-24. PubMed ID: 10815358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Preliminary Cost-Utility Analysis of the Prosthetic Care Innovations: Basic Framework.
    Frossard L
    Can Prosthet Orthot J; 2021; 4(2):36365. PubMed ID: 37614995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The lag from FDA approval to published cost-utility evidence.
    Chambers JD; Thorat T; Pyo J; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results.
    Zhou J; Millier A; François C; Aballéa S; Toumi M
    J Mark Access Health Policy; 2019; 7(1):1648973. PubMed ID: 31489150
    [No Abstract]   [Full Text] [Related]  

  • 30. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the value for money of medicines? A registry study.
    Simoens S
    J Clin Pharm Ther; 2012 Apr; 37(2):182-6. PubMed ID: 21812796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A scoping review of pediatric economic evaluation 1980-2014: do trends over time reflect changing priorities in evaluation methods and childhood disease?
    Sullivan SM; Tsiplova K; Ungar WJ
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):599-607. PubMed ID: 27659998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.
    Fryback DG; Lawrence WF
    Med Decis Making; 1997; 17(3):276-84. PubMed ID: 9219187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses.
    Bell CM; Chapman RH; Stone PW; Sandberg EA; Neumann PJ
    Med Decis Making; 2001; 21(4):288-94. PubMed ID: 11475385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies.
    Chapman RH; Stone PW; Sandberg EA; Bell C; Neumann PJ
    Med Decis Making; 2000; 20(4):451-67. PubMed ID: 11059478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and quality of pediatric cost-utility analyses.
    Kromm SK; Bethell J; Kraglund F; Edwards SA; Laporte A; Coyte PC; Ungar WJ
    Qual Life Res; 2012 Oct; 21(8):1315-25. PubMed ID: 22038397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raising the quality of cost-utility analyses: lessons learnt and still to learn.
    Gerard K; Smoker I; Seymour J
    Health Policy; 1999 Mar; 46(3):217-38. PubMed ID: 10351669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    Simões Corrêa Galendi J; Vennedey V; Kentenich H; Stock S; Müller D
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638366
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.